Single Dose Pharmacokinetics of Oral Dextran Sulfate (UA001) and Intravenous Dextran Sulfate in Healthy Volunteers

You may not be if

• Co-existing Condition:
• Volunteers with any of the following are excluded:
• Disorders of coagulation or disorders of plasma lipids.
• Allergy to dextran sulfate, other sulfates, other dextrans.
• Concurrent Medication:
• Excluded:
• Volunteers who anticipate need for medication during study.
• Volunteers with any of the following are excluded:
• Disorders of coagulation or disorders of plasma lipids.
• Allergy to dextran sulfate, other sulfates, other dextrans.
• Prior Medication:
• Excluded within 2 weeks of study entry:
• Any medication.
• Risk Behavior:
• Excluded:
• Ingestion of alcohol within 48 hours prior to study.
• History of recent drug or alcohol abuse.
• Disorders of coagulation or disorders of plasma lipids.
• Allergy to dextran sulfate, other sulfates, other dextrans.
• Volunteers selected are:
• In good general health as determined by screening history, physical examination, and laboratory panel within established limits of normal for hospital laboratory.
• Consenting volunteers.
• Available for 6 days of continuous hospitalization.